Which extended‑release diltiazem formulation is a coated‑bead product?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Extended-Release Diltiazem Formulations

The coated-bead extended-release diltiazem formulation is not explicitly identified by brand name in the provided evidence, but coated-bead technology using polymers like Eudragit® is a well-established method for achieving sustained release of diltiazem hydrochloride.

Understanding Diltiazem Extended-Release Technologies

Extended-release diltiazem formulations utilize various pharmaceutical technologies to achieve sustained drug delivery:

Coated-Bead Systems

  • Polymer-coated beads represent one approach to modified release, where diltiazem-containing beads are coated with functional polymers 1
  • Eudragit® RS and RL 30D are cationic copolymers frequently used for coating solid dosage forms, including diltiazem beads 1
  • These coatings contain quaternary ammonium groups that theoretically provide pH-independent release, though actual release is influenced by ionic interactions with buffer species 1

Alternative Technologies

Recent pharmaceutical innovations for diltiazem modified-release include 2:

  • Hydrophilic matrices using HPMC
  • Coated pellets with ethylcellulose or Eudragit®
  • Microspheres prepared via spray drying or solvent evaporation
  • Osmotic systems
  • Ion-exchange resin complexes using cation-exchange resins as single excipients 3

Clinical Dosing Context

According to FDA labeling 4, standard immediate-release diltiazem tablets may be swallowed whole, crushed, or chewed, with dosing typically 30-120 mg four times daily. Extended-release formulations mentioned in guidelines 5, 6, 7, 6 reference "120-360 mg daily in divided or single dose with long-acting formulations" 6, 7, 6, though specific bead-coating technology is not detailed.

Important Caveat

The provided evidence does not specify commercial brand names that definitively use coated-bead technology versus other extended-release mechanisms. Multiple extended-release diltiazem products exist in clinical practice, and determining which specific formulation uses coated-bead technology would require consulting individual product prescribing information or contacting manufacturers directly.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.